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Background
Cognitive–behavioural therapy (CBT) is the treatment of choice
for generalised anxiety disorder (GAD), yielding significant
improvements in approximately 50% of patients. There is sig-
nificant room for improvement in the outcomes of treatment,
especially in recovery.
Aims
We aimed to comparemetacognitive therapy (MCT) with the gold
standard treatment, CBT, in patients with GAD (clinicaltrials.gov
identifier: NCT00426426).
Method
A total of 246 patients with long-term GAD were assessed and
81 were randomised into three conditions: CBT (n = 28), MCT
(n = 32) and a wait-list control (n = 21). Assessments were made
at pre-treatment, post-treatment and at 2 year follow-up.
Results
Both CBT andMCTwere effective treatments, but MCTwasmore
effective (mean difference 9.762, 95% CI 2.679–16.845, P = 0.004)
and led to significantly higher recovery rates (65% v. 38%). These
differences were maintained at 2 year follow-up.
Conclusions
MCT seems to produce recovery rates that exceed those of CBT.
These results demonstrate that the effects of treatment cannot
be attributed to non-specific therapy factors.
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Generalised anxiety disorder (GAD) is a prevalent and disabling
disorder characterised by persistent worrying, anxiety symptoms
and somatic complaints. An intense experience of uncontrollable
and distressing worry over a number of topics is at the centre of
the disorder.1 GAD impairs work and social functioning with
increasing severity if left untreated.2 It is one of the most frequent
anxiety disorders in primary care, being present in 22% of primary
care patients who suffer anxiety and depressive problems.3 There
are eight meta-analyses of randomised controlled trials of GAD
in adults4–11 and two in older adults.12,13 Most published trials
have tested the effects of different drugs, different types of cogni-
tive–behavioural therapy (CBT) or treatments using relaxation
therapies. Only two meta-analyses have a broader approach and
assess all psychological treatments,7,11 and only one includes
both CBT and pharmacotherapy, predominantly benzodiaze-
pines.5 The psychotherapy of choice for GAD is CBT,14 which is
the most empirically supported treatment.10,11 CBT produces sig-
nificant improvement in GAD at 2 years follow-up,15 and approxi-
mately 50% of patients are clinically improved.7,16 A more recent
approach to GAD that appears to be particularly effective is meta-
cognitive therapy (MCT).17 Data from randomised trials of
anxiety and depression have shown recovery rates in MCT of
72–80%. This treatment has demonstrated greater efficacy in
GAD compared with applied relaxation18 or treatment based on
the intolerance of uncertainty model.19 MCT is a good comparator
for CBT as MCT appears effective and does not include cognitive
restructuring, exposure, applied relaxation or breathing techni-
ques, which are at the core of CBT, thereby minimising overlap.
We set out to address the following question: Which is the most
effective, MCT or the gold-standard CBT, when we use the same
therapists in both conditions under supervision of the originators
of these therapies?
Method
The study was conducted at the university outpatient clinic at the
Norwegian University of Science and Technology in Trondheim
from 2008 to 2016, and was approved by the Regional Committee
for Medical and Health Research Ethics (SAK: 4/2006/2369;
Clinicaltrials.gov identifier: NCT00426426). A total of 246 patients
were referred to the study, and 81 were eligible for, and included in
the trial (Fig. 1). They were randomised into three treatment condi-
tions: CBT (n = 28), MCT (n = 32) and a wait-list control (n = 21).
Patients were assessed at pre-treatment, post-treatment and at
2 year follow-up. The wait-list participants were offered treatment
after 12 weeks post-randomisation. We used a crossover design of
therapists to control for therapist factors. Three therapists used
CBT and the other three used MCT on the first half of the patients.
Halfway into the trial, the therapists were crossed over and delivered
the other treatment condition.
The eligibility and inclusion criteria were a diagnosis of GAD,
giving written consent before entry in the study and aged 18 years
or older. Patients not willing to withdraw psychotropic medication
for a period of 3 weeks before entry to the trial were not included but
received treatment outside of the trial. The exclusion criteria were
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known somatic diseases, psychosis, recent suicidal attempts and/or
current intent, primary post-traumatic stress disorder, cluster A or
cluster B personality disorder, substance dependence or unwilling-
ness to accept random allocation. A summary of the demographic
characteristics can be found in Table 1.
Procedures and assessments
The participants were administered a structured interview by inde-
pendent assessors, and included the Anxiety Disorders Interview
Schedule for DSM (ADIS-IV)20 and the DSM Structured Clinical
Interview for Axis II (SCID-II).21 All assessment interviews were
videotaped and reviewed to assess diagnostic agreement. Assessors
were blind to treatment condition. Independent evaluators were
trained and certified on the rating instruments and ADIS-IV and
SCID-II assessments. The interrater reliability of independent asses-
sors was based on randomly selected videotaped assessments. The
study interrater reliability for a diagnosis of GAD was κ = 0.90,
and for major depressive disorder it was κ = 0.74. After treatment,
the evaluators were blinded before assessment.
Randomisation and masking
Trial participants were randomly assigned to one of three condi-
tions, using the IBM random number generator program.
Randomisation was stratified by gender and by DSM-IV22
major depressive disorder, and the randomisation sequence
was prepared by the trial statistician, who was independent of
patient recruitment.
Therapists
Six clinical psychologists, who had all received extensive training
in both CBT and MCT, were selected for the trial. They received
regular and equivalent amounts of training and supervision
from the originators of the manuals (CBT: T.D.B; MCT: A.W.).
All therapists were rated by independent assessors for adher-
ence, competency level and their working alliance with their
clients. In addition, by using self-report instruments, the thera-
pists were measured on expectancy of the suitability of the treat-
ment and the credibility in the treatment they were applying to
the patient.
Randomised (n=81)
Lost to follow-up  n=2
Discontinued intervention n=2
- Declined to participate
- Somatic illness
Assessed for eligibility (n=246) 
Allocated to MCT n=32
Received intervention n=32
Did not receive n=0
Allocated to wait-list n=21
Received intervention n=0
Did not receive n=21
Allocated to CBT n=28
Received intervention n=28
Did not receive n=0
Lost to follow-up  n=2
Discontinued intervention n=2
- Moved to new city
- Declined to participate
Excluded (n=165)
- 62  Did not meet inclusion criteria
- 71  GAD not primary diagnosis




Excluded from analysis n=0
Analysed n=28
Excluded from analysis n=0
Analysed n=21










We used published treatment manuals of CBT14 and MCT.17
Treatments were applied for a maximum of 12 weekly sessions
of 60 min duration. CBT treatment consisted of four modules:
detecting early cues of anxiety and worry, applied relaxation as
a response to these cues, imaginal rehearsal of coping methods
with self-control desensitisation and CBT on catastrophic
beliefs and worry. Patients receiving CBT were informed in the
rationale of the treatment that imaginal rehearsal of coping
methods would facilitate fear and worry reduction and develop-
ment of new coping responses, cognitive therapy would reduce
anxiety-maintaining thoughts and beliefs and use of cognitive
therapy during imaginal rehearsal would provide cognitive coping
along with relaxation skills.
We used detection of anxiety cues and applied relaxation in the
first three sessions. Self-control desensitisation began in session
four, cognitive therapy began in session five and both were con-
ducted in every session thereafter. During desensitisation, after
the client was deeply relaxed, external and internal worry cues
were presented until the client signalled the presence of anxiety.
The client then continued imagining the external situation while
imaging that he or she was using relaxation skills in that situation.
At the elimination of anxious feelings, he or she imagined continued
use of these skills for 20 s and then turned off all imagery and
focused only on relaxation for 20 s. The scenes were repeated
until the client could no longer generate anxiety or was able to elim-
inate it rapidly (5–10 s). Cognitive therapy was used up to 15 min
per session. The primary goal was to produce cognitive coping
responses (both self-statements and perspective shifts) for use
during desensitisation; if time or client readiness allowed, we
placed emphasis on applying cognitive therapy skills more generally.
The cognitive therapy included thought and belief identification,
logical analysis with probability, and evidence searching to develop
alternative thoughts.
In MCT, the patients’ metacognitive beliefs were targeted.
Metacognitive beliefs refer to beliefs about thinking, such as the
belief that worry is uncontrollable or overthinking is harmful.
The metacognitive beliefs were challenged by verbal means and
by behavioural experiments with a main emphasis on negative
beliefs about worry, specifically its uncontrollability and dangerous-
ness. In MCT the goal is elimination of negative metacognitive
beliefs and the introduction of an alternative set of strategies so
that the patient is better able to regulate worry and step back
from triggering thoughts. MCT for GAD consists of five modules:
case formulation and socialisation (sessions one and two), modify-
ing beliefs about uncontrollability and danger of worry (sessions
three to six), challenging positive beliefs about the utility and advan-
tages of worry (sessions seven and eight), implementation of alter-
native coping strategies (sessions nine and ten) and relapse
prevention (sessions 11–12). The rationale given to patients is
that worrying can be controlled by disengaging from trigger thoughts
and postponing further conceptual processing; mental events do not
matter, only responses to them do; worrying is harmless and there
are no advantages to worrying.
Measures of outcome
The primary outcomemeasure was worry severity at post-treatment
measured by the Penn State Worry Questionnaire (PSWQ),23 a
16-item measure of worry that has evidenced internal consistency,
and factor analysis indicated that the PSWQ assesses a unidimen-
sional construct with high convergent and discriminant validity of
the measure.24 PSWQ was assessed at post-treatment across the
three groups and at follow-up for the MCT and CBT groups.
Table 1. Demographic and clinical characteristics of patients with generalised anxiety disorder in the sample
Characteristic CBT (n = 28) MCT (n = 32) Wait-list (n = 21) Total (n = 81) F/χ2 P
Age, mean (s.d.) 38.61 (10.9) 36.96 (14.02) 37.86 (12.72) 37.75 (12.54) 0.130 0.878
Female, n (%) 19 (68) 24 (75) 16 (76) 59 (73) 0.539 0.764
Social status, n (%) 12.31 0.421
Single 3 (21) 7 (50) 4 (29) 14 (18)
Married/cohabiting 17 (32) 22 (41) 14 (27) 53 (65)
Separated/widowed 1 (33.3) 2 (66.6) 0 (0) 3 (4)
Not reported 7 (64) 1 (9) 3 (27) 11 (13)
Ethnicity, n (%) 2.91 0.573
White 27 (96) 31 (96) 20 (95) 78 (96)
Other 1 (4) 1 (4) 1 (5) 3 (4)
Work status, n (%) 60.80 0.864
Full time/partial 23 (82) 21 (65) 14 (66) 58 (71)
Unemployed 1 1 1 3 (3.8)
Student 2 6 4 12 (15)
Sick leave 2 3 2 7 (8.8)
Disability pension 0 1 0 2 (2.4)
Comorbid diagnoses, mean (s.d.) 2.43 (1.26) 2.34 (1.20) 2.52 (1.20) 2.41 (1.21) 0.364 0.696
Major depressive disorder, n (%) 14 (33) 15 (35) 13 (32) 42 1.408 0.495
Episode, n 2 3 1 6
Recurrent, n 8 11 10 29
Dysthymia, n 4 1 2 7
Agoraphobia, n 2 2 3 7 1.159 0.560
Social phobia, n 8 9 7 24 0.188 0.910
Specific phobia, n 2 6 1 9 3.194 0.202
Panic disorder, n 7 2 3 12 4.166 0.125
Obsessive–compulsive disorder, n 1 1 0 2 0.730 0.694
Somatisation/hypochondria, n 2 2 2 6 0.203 0.904
Eating disorder, n 1 3 1 5 0.966 0.617
Avoidant PD, n 2 2 2 6 0.203 0.904
Dependent PD, n 2 2 3 7 1.159 0.560
CBT, cognitive–behavioural therapy; MCT, metacognitive therapy; PD, personality disorder.
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The secondary measures also included: trait anxiety (State-Trait-
Anxiety Inventory; STAI-T),25 anxiety symptom severity (Beck
Anxiety Inventory; BAI)26 and interpersonal difficulties (Inventory
of Interpersonal Problems; IIP-64).27 We also used the Beck Depression
Inventory26 to control for depressive symptoms.
Non-specific factors in therapy
Non-specific factors in therapy may vary between the treatment
conditions and may be an alternative explanation for any difference
in the observed outcome. Thus, we decided to perform a thorough
assessment of these potent factors. Therapeutic alliance was mea-
sured using the Working Alliance Inventory (WAI).28 The WAI
was adapted to a rating scale and we used 12 items to rate alliance,
with scores from 0–7 on a Likert scale. The patients answered this
form at the end of session three.
The therapists’ expectancy and credibility in the therapy were
measured by The Credibility-Expectancy Questionnaire (CEQ),29
which is a self-report measure. Therapeutic expectancy was mea-
sured at session three for all therapists and refers to the therapist’s
predictions about the likelihood that a certain therapy will reduce
symptoms. Therapeutic credibility refers to the degree a treatment
makes sense to the therapist and seems like a logical and feasible
treatment. The CEQ has high internal consistency and high test-
rest reliability.30 The CEQ is scored on a scale from 0 to 100 of
how much the therapist believes in the treatment and in their con-
fidence in being able to implement it.
Wemeasured adherence and competency inCBTwith an adapted
version of the Cognitive Therapy Competency and Adherence Scale
(CTACS),31 and in MCT we used the Metacognitive Therapy
Competency Scale (MCT-CS).32 The independent assessors of the
study collaborated with the originators of the treatments in the
assessment of the therapists. Each therapist was assessed on 50%
of their CBT sessions and 50% of their MCT sessions. Their
scores were calculated on both adherence to the protocol and to
competency by the checklists for adherence and standardised com-
petency scales. For competency assessed on CTACS in CBT and on
MCT-CS inMCT, we used a 0–5 competency level (0, no competency
to 5, expert level).
Statistical analysis
All data were analysed according to the intention-to-treat principle.
We had very fewmissing data and we analysed data with the multiple
imputationmethod for mixedmodels33 and last-observation-carried-
forward method. Both methods showed similar results. Categorical
data were analysed by chi-squared tests and pre-treatment group dif-
ferences on unadjusted dimensional self-report measures were tested
with analysis of variance (ANOVA). The primary outcome (PSWQ
score) and secondary outcomes (STAI-T, BAI and IIP-64 scores)
measures were subjected to general mixed-model analysis repeated-
measures ANOVA, with treatment condition as the between-
groups factor and time (pre-treatment, post-treatment and 2 year
follow-up) as the repeated-measures factor. The analyses were con-
ducted separately for the effects at post-treatment and 2 year
follow-up (the control group was not measured at follow-up).
We also ran analysis of covariance (ANCOVA) on the PSWQ
and STAI-T scores, followed with Sidak pairwise post hoc compar-
isons on the adjusted means. Between-group effect sizes are
reported as partial eta-squared (ηp
2). We also computed controlled
effect sizes with Cohen’s formula (d)34 by subtracting the post-
treatment means from the post-wait-list means and dividing this
by the pooled s.d. We determined the clinical significance of find-
ings by applying the two-fold Jacobson and Truax criteria (combin-
ing criteria a and c)35 for defining rates of reliable clinical change and
recovery across groups. In a follow-up exploratory analysis we ran a
mixed-model ANOVA including the crossover factor (MCT or CBT
first/second), to test for anymain effects of order of training or inter-
action between order and therapy type. Because of repeated testing
on the primary outcome (PSWQ score), we corrected for multiple
comparisons on thismeasure by Bonferroni correction with a signifi-
cance level set at α = 0.017. The significance level in the secondary
outcomes were not adjusted and remained at α = 0.05, as these
were exploratory and we did not want to force a type II error. We
used IBM SPSS version 24 for Windows in the statistical analysis.
Statistical power
Statistical power analysis was based on the minimum clinically
meaningful difference between treatments on the PSWQ, which
we set at eight points with a normative s.d. on the PSWQ of 8.36
With a probability of type I error of 5% and with the aim of 30
patients included in each of the treatment groups, we calculated
the power of the statistical analysis to detect a significant differences
to be 0.9314. Thus, with 30 participants in each arm there was a
93.1% chance of detecting a difference at the 5% level of significance
between the groups.
Results
T.D.B. wants to express that he has argued in previous publications
that comparative outcome designs should not be conducted because
of their potentially limited scientific and applied value. The present
study represents an effort, as best as possible, to eliminate the most
serious methodological problems commonly associated with those
designs. This study is a rare example of having each therapist
treat participants in each therapy, thus removing therapist charac-
teristics as a major confounding factor. Also, assessment of therapist
competence, as performed in this study, is a move in the direction of
reducing the likelihood that differences in quality of the therapies
explain any differential outcome. Thus, although other cautions in
interpreting the results remain,37 the main impediments to unam-
biguous interpretation of the results have been mitigated.
Demographic and clinical characteristics
Table 1 provides demographic and clinical data for the sample.
There were no significant differences in age (P = 0.878), gender
(P = 0.764), social (P = 0.421) or work (P = 0.864) status or ethnicity
(P = 0.573). There were no significant differences in the presence of
concurrent major depressive disorder (P = 0.495), number of
current comorbid disorders (P = 0.696), in the distribution of avoi-
dant personality disorder (P = 0.904) or in any specific additional
disorders among the three conditions.
Primary outcome
The results of the general mixed-model ANOVA from pre- to post-
intervention across the three groups (CBT, MCT and wait-list)
showed that there was a significant main effect for group (F(2,78) =
12.573, P < 0.01, ηp
2 = 0.244) on the PSWQ (Table 2). There was an
overall effect of time indicating significant improvements (F(1,78) =
104.093, P < 0.01, ηp
2 = 0.572) and also a significant group×time
interaction (F(2,78) = 17.626, P < 0.01, ηp
2 = 0.3110).
The interaction term demonstrated that there was a different
magnitude of improvement across the groups. Inspection of visual
plots showed that both treatment groups improved more than the
control group, with the MCT condition showing the greatest
improvement.
We then calculated follow-up between-group ANCOVAs, con-
trolling for pre-treatment scores on the respective post-treatment
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outcome variables and computed pairwise post hoc Sidak tests on
the adjusted means. For PSWQ score, the covariate effect was sig-
nificant (F(1,77) = 20.838, P < 0.01, ηp
2 = 0.213) and there was a sig-
nificant effect for group (F(2,77) = 18.762, P < 0.01, ηp
2 = 0.328). The
pairwise tests showed that the CBT group had a lower post-treat-
ment score than the wait-list group (mean difference 9.337, s.e.
3.201, 95% CI 1.524–17.150, P = 0.014). Similarly, the MCT group
was lower than the control group (mean difference 19.099, s.e.
3.142, 95% CI 11.430–26.768, P < 0.01), and crucially, it was also
lower than the CBT group (mean difference 9.762, s.e. 2.902, 95%
CI 2.679–16.845, P < 0.01).
Secondary outcomes
Next, we ran ANCOVAs on the 2 year follow-up data from the two
treated groups only (Table 2). For the PSWQ the covariate effect was
significant (F(1,57) = 14.162, P < 0.01, ηp
2 = 0.199), as was the effect
of group (F(1,57) = 4.339, P = 0.04, ηp
2 = 0.071), in favour of MCT.
In summary, the tests on the primary outcome showed a better
outcome of MCT over CBT post-treatment and this superiority
was present at 2 year follow-up.
There was a group main effect on the STAI-T (F(2,78) = 6.168,
P < 0.01, ηp
2 = 0.137) and an effect of time (F(1,78) = 65.778, P < 0.01,
ηp
2 = 0.457). The group×time interaction was also significant
(F(2,78) = 8.406, P < 0.01, ηp
2 = 0.177). In the ANCOVA, controlling
for STAI-T at pre-treatment, there was an effect of the covariate
(F(1,77) = 28.456, P < 0.01, ηp
2 = 0.270) at post-treatment and an
effect of group (F(2,77) = 10.709, P < 0.01, ηp
2 = 0.218). Pairwise tests
showed that scores were lower after CBT than in the wait-list group
(mean difference 7.333, s.e. 2.670, 95% CI 0.817–13.850, P = 0.02),
and also lower after MCT compared with the wait-list group (mean
difference 12.094, s.e. 2.613, 95% CI 5.716–18.473, P < 0.001). The dif-
ference between CBT and MCT was not significant (mean difference
4.761, s.e. 2.393, 95% CI −1.081 to 10.603, P = 0.143).
At 2 year follow-up the STAI-T covariate effect was significant
(F(1,57) = 8.561, P < 0.01, ηp
2 = 0.131), although the group effect
failed to reach significance (F(1,57) = 3.956, P = 0.05, ηp
2 = 0.065).
In summary, although there were lower scores on the STAI-T
after MCT and CBT at post-treatment when compared with the
wait-list, differences between MCT and CBT at post-treatment
and follow-up were non-significant.
The results of the linear mixed-model, repeatedmeasures for the
BAI and the IIP-64 were as follows. On the BAI there was a group
(F(2,78) = 8.370, P < 0.001, ηp
2 = 0.177) and time effect (F(1,78) =
85.391, P = 0.01, ηp
2 = 0.523) and a significant group×time inter-
action (F(2,78) = 8.513, P = 0.01, ηp
2 = 0.179). On the IIP-64 the
group effect was significant (F(2,78) = 6.329, P < 0.01, ηp
2 = 0.140),
as was the time effect (F(1,78) = 43.393, P < 0.01, ηp
2 = 0.357) and
the interaction term (F(2,78) = 6.820, P < 0.01, ηp
2 = 0.149).
We conducted ANCOVAs by controlling for the pre-treatment
scores. This showed that on the BAI there was an covariate effect
(F(1,77) = 25.023, P < 0.01, ηp
2 = 0.245) and a group effect (F(2,77) =
16.692, P < 0.01, ηp
2 = 0.302), with MCT performing significantly
better at post-treatment than both CBT (mean difference 6.673,
s.e. 2.474, 95% CI 0.633–12.712, P = 0.02) and wait-list (mean dif-
ference 15.553, s.e. 2.697, 95% CI 8.969–22.137, P < 0.001). CBT
was significantly better at post-treatment than the wait-list (mean
difference −8.880, s.e. 2.819, 95% CI 1.999–15.761, P < 0.01). At
2 year follow-up, MCT was no longer significantly better than
CBT (F(1,57) = 3.673, P = 0.06, ηp
2 = 0.061).
On the IIP-64 there was an effect of group (F(2,77) = 10.854, P <
0.01, ηp
2 = 0.220) and a covariate effect (F(1,77) = 66.830, P < 0.01, ηp
2
= 0.465) at post-treatment, with MCT performing better than both
CBT (mean difference −0.335, s.e. 0.101, P < 0.01) and wait-list
(mean difference −0.480, s.e. 0.109, P < 0.01). CBT did not perform
better than the wait-list (P = 0.47). At 2 year follow-up, MCT per-
formed better than CBT (F(1,57) = 7.694, P < 0.01, ηp
2 = 0.119; mean
difference 0.312, s.e. 0.113, 95% CI 0.087–0.537, P < 0.01) and the
covariate was significant (F(1,57) = 29.219, P < 0.01, ηp
2 = 0.339).
Non-specific factors and order effects
The trial used six clinical psychologists and all were trained by the ori-
ginators of the treatment protocols. The therapists were randomised
into delivering either CBT first or MCT first, and all therapists
swapped treatment condition by mid-trial. The mean score for the
CEQ for MCT was 92% (s.d. 6.86, range 80–100) and for CBT it was
87.4% (s.d. 10.74, range 70–100), and the difference on an independent
sample t-test was not significant (t = 1.633, P = 0.109).
In CBT the adherence rate was 82% (s.d. 7.31) and the compe-
tency level across all six therapists was 3.60 (s.d. 0.56). In the MCT
condition the adherence rating was 76% (s.d. 15.00) and compe-
tency level was 3.24 (s.d. 0.74). There were significant differences
between CBT and MCT in competency level (t(31) = 2.063, P <
0.01) in favour of CBT, but not in adherence to the protocols
(P = 0.26). The mean score for the WAI in CBT was 5.54 (s.d.
0.709) and for the MCT group it was 5.75 (s.d. 0.594), with no
significant difference between the groups (P = 0.23).
Table 2. Unadjusted means and s.d. at pre-treatment, post-treatment and 2 year follow-up, with pairwise comparisons across assessments
Measure
CBT (n = 28),
mean (s.d.)
MCT (n = 32),
mean (s.d.)
Wait-list (n = 21),
mean (s.d.) F/t P
Pairwise comparisons (P)
CBT versus MCT CBT versuswait-list MCT versus wait-list
Penn State Worry Questionnaire
Pre-treatment 67.60 (6.28) 65.10 (8.47) 67.52 (7.60) 1.12 0.33 0.461 0.998 0.557
Post-treatment 54.67 (12.80) 42.93 (14.09) 63.95 (8.49) 18.84 <0.001 <0.001 0.034 <0.001
2 year follow-up 53.30 (13.25) 45.41 (15.19) 2.50 0.015 0.015
Spielberger Trait Anxiety Inventory
Pre-treatment 57.07 (8.50) 55.76 (9.01) 58.52 (8.06) 0.66 0.519 0.913 0.915 0.588
Post-treatment 47.39 (11.28) 41.78 (12.05) 55.66 (7.19) 10.61 <0.001 0.134 0.027 <0.001
2 year follow-up 45.96 (11.13) 43.53 (9.7) 2.08 0.041 0.041
Beck Anxiety Inventory
Pre-treatment 21.46 (10.05) 24.47 (13.82) 28.85 (12.85) 2.14 0.125 0.727 0.121 0.508
Post-treatment 10.42 (12.80) 5.06 (5.57) 22.52 (13.84) 16.53 <0.001 0.170 0.001 <0.001
2 year follow-up 9.85 (9.72) 6.34 (7.82) 1.54 0.127 0.127
Inventory Interpersonal Problems-64
Pre-treatment 1.35 (0.55) 1.11 (0.50) 1.31 (0.51) 1.78 0.175 0.225 0.992 0.225
Post-treatment 1.08 (0.54) 0.58 (0.44) 1.19 (0.58) 11.05 <0.001 <0.001 0.815 <0.001
2 year follow-up 1.14 (0.51) 0.69 (0.51) 3.35 0.001 0.001
Test of significance – two-tailed. CBT, cognitive–behavioural therapy; MCT, metacognitive therapy.
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To check for order effects, we analysed the PSWQ data (time
points 1–3: pre-treatment, post-treatment and follow-up), using
treatment order as a category variable, using a 2 groups × 2
(order) × 3(time points 1–3) mixed model. The results showed
no main effect of order. There was no interaction of order and
time (F(2,112) = 0.293, P = 0.74, ηp
2 = 0.0050) and no three-way
interaction between group, order and time (F(2,112) = 0.264,
P = 0.76, ηp
2 = 0.005). Therefore, it did not seem to make any
difference to the outcome if the therapist delivered a specific treat-
ment first or second.
Effect sizes, reliable improvement and recovery rates
To compare the standardised magnitude of improvement in worry
and anxiety symptoms, we calculated pre-treatment to post-treat-
ment and follow-up effect sizes (d) with Cohen’s formula33 on
our primary variable, PSWQ score, and we supplemented this
with the STAI-T score as this measure is also commonly used in
earlier treatment studies, providing a point of reference (Fig. 2).
The controlled effect sizes are the most relevant and were calculated
as the difference between each active treatment condition at post-
treatment and the wait-list expressed in s.d. (pooled) units. For
PSWQ at post-treatment, CBT versus wait-list was dc = 0.86 and
MCT versus wait-list was dc = 1.73. For STAI-T, CBT versus wait-
list was dc = 0.87 and MCT versus wait-list was dc = 1.42.
To obtain an estimate of the clinical significance of treatment
effects on the PSWQ score, we calculated the Reliable Change
Index.34 We used a twofold criterion here of at least a 2-point s.d.
change and also a score below the clinical cut-off. The number of
patients meeting these criteria for complete recovery after treat-
ment, according to the PSWQ, was 38% in the CBT group, 65%
in the MCT group and none in the wait-list (Table 3). At 2 year
follow-up these effects were mainly upheld (31% v. 57%). There
was a significant difference between MCT and CBT in recovery
rates both at post-treatment (P < 0.01) and at 2 year follow-up, in
favour of MCT (P = 0.01).
Discussion
This study compared, for the first time, CBTwithMCT in the short-
and long-term and controlled for non-specific therapy factors. MCT
had better outcomes than CBT on most comparisons. Rates of clin-
ical response, defined as recovery on the PSWQ, demonstrated that
overall 65% of patients were recovered after MCT compared with
38% after CBT. The current results for CBT corresponds well
with results obtained in other studies and by Borkovec and
Costello.14 The outcome for MCT are similar to or slightly lower
than those obtained in other studies.18,19 This suggests that the out-
comes are consistent and representative of the effects normally seen
with these treatments.
GAD has high comorbidity with depressive disorder, alcohol,
benzodiazepine dependency and somatoform disorders,1 and
most patients struggle with GAD for 8–10 years, with low rates of
remission even when treated. This has led some to characterise it
as a chronic disorder.2 However, the results of this study combined
with other published studies of MCT suggest that CBT and MCT
can lead to positive outcomes. Furthermore, these results appear
to exist independently of non-specific treatment factors, which
appears to support the substantive differential effects of treatment
approaches.
Why is there a different response between CBT and MCT? In
this study we took great care in training therapists to high standards,
using protocols and measuring therapist expectancy and compe-
tency as well as assessing the quality of the working alliance.
There were few differences in these dimensions across the active
treatment conditions. An unexpected difference that did emerge
was that therapists were rated as less competent in delivering
MCT than CBT. The superiority ofMCT in the current trial is there-
fore unlikely to be because of greater competency levels. It seems
more likely that the differences observed can be accounted for by
the different focus and techniques used in these therapies. In par-
ticular, CBT focuses on reducing the amount of worry through
applied relaxation, general cognitive therapy and coping rehearsal
during imaginal exposures. In contrast, MCT focuses on reducing
worry by modifying metacognitive beliefs about the uncontrollabil-
ity and dangerousness of worry. CBT focuses predominantly on
physiological and emotional cues for anxiety and worry, whereas
MCT eschews this aspect and focuses on metacognitive responses
such as choosing to leave thoughts alone. Thus, the specific elements
in each therapy seem to play an important role and this interpret-
ation becomes more compelling given few observed differences in
non-specific factors between conditions, as is the case here. We
found that the wait-list condition improved over time. This may
reflect spontaneous recovery or regression to the mean, but the
results demonstrate the importance of control conditions in inter-
preting the magnitude of true treatment effects.
Some notable strengths of the study are the use of a randomised
controlled design with clearly defined and reliable measures. We
used the originators of the treatment modalities in this study to
train all therapists up to acceptable standards and assessed alle-
giance, competence and adherence to the protocol. In a crossover
design the therapists swapped treatment modality halfway
through the study, so the potential effect of therapist factors was
balanced. By balancing the therapist factors, we can reduce the
bias in the interpretation of between-condition effects.
There are also some important limitations to consider. First, a sig-
nificant proportion of the data for 1 year follow-up in the CBT group
Table 3. Classification of recovery, reliably improved, no change and
deteriorated on the Penn State Worry Questionnaire by completers at
post-treatment and by 2 year follow-up
CBT (n = 26) MCT (n = 31) Wait-list (n = 21) P
Post-treatment <0.01
Recovered 10 (38) 20 (65) 0
Improved 9 (35) 5 (16) 7(33)
No change 7 (27) 6 (19) 14 (67)
Deteriorated 0 (0) 0 (0) 0 (0)
2 year follow-up CBT (n = 26) MCT (n = 30) <0.01
Recovered 8 (31) 17 (57)
Improved 10 (38) 10 (33)
No change 8 (31) 2 (7)
Deteriorated 0 (0) 1 (3)












Fig. 2 Recovery rates (%) of completers in each condition after




were not collected at the correct time because of an administrative and
logistic failure. Thus, it was decided by the steering group that we
should not continue to collect and publish these data, but instead
divert all efforts to the 2 year follow-up. Second, the outcomemeasures
were predominantly based on self-report assessments, which could be
affected by patient bias. However, Cuijpers et al11 reported from their
recent meta-analysis of GAD that self-report assessments were lower
than those of the clinician-rated outcomes (therapist bias). Thus, it
seems that patients may underestimate any changes, which indicates
that self-reported outcome does not present an inflated result com-
pared with clinician-rated outcome. Third, the level of competency
in the methods was unequal, where the level of CBT was rated
higher than MCT. This was not in favour of MCT, and therefore
greater competency does not seem to explain the superiority of
MCT. The difference in competency could be a result of characteristics
of the method, the newer and unfamiliar status of MCT or more prior
training in CBT.
In conclusion, both CBT and MCT were effective in reducing
worry and anxiety symptoms in GAD both in the short- and long-
term. However, MCT had a better outcome in reducing worry at
post-treatment and in recovery rates at post-treatment and follow-
up. In future, highly controlled studies are important to inform
healthcare policy on themost appropriate forms of therapy in treating
GAD and anxiety disorder in general. In contrast with previous
assumptions, GAD can be effectively treated with long-term benefits,
and treatments with differential levels of efficacy can be determined.
An important implication of these findings is that future meta-ana-
lyses will need to take special care in forming meaningful and valid
clusters of treatment types for analysis so that important and emer-
ging differences between treatments are not obscured.
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